27
Nov
Press Release Here.
Clinical Trial of Investigational Ebola Treatments Begin In Democratic Republic Of Congo
Antibody-based Contraceptive Research Center Awarded to Boston University Led Consortium
17
Oct
Click here for press release. Antibody-based Contraceptive Research Center Awarded to Boston University Led Consortium October 17, 2018– Investigators from Boston University School of Medicine and Mapp Biopharmaceutical Inc. are heading up a new Contraceptive Research Center (CRC) funded by an $8M grant from the Eunice Kennedy Shriver National Institute
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure
28
Sep
MappBio Announces Contract with BARDA for Sudan Ebolavirus Medical Countermeasure September 28, 2018 – (SAN DIEGO, CA) – Mapp Biopharmaceutical, Inc. (MappBio), announced today that it has been awarded a contract (HHSO100201800024C) of $14.8 million with options for an additional $32.0 million by the Biomedical Advanced Research and Development Authority (BARDA),
MappBio Announces Contracts with BARDA for ZMappTM and Additional Filovirus Medical Countermeasures
29
Sep
MappBio Announces Contracts with BARDA for ZMappTM and Additional Filovirus Medical Countermeasures Sep 29, 2017—(SAN DIEGO, CA)— Mapp Biopharmaceutical, Inc., announced today that it has been awarded a Project BioShield contract (HHSO100201700017C) of approximately $46 million by The Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the
Researchers Discover First Human Antibodies That Work Against All Ebolaviruses
19
May
Researchers Discover First Human Antibodies That Work Against All Ebolaviruses May 18, 2017—(BRONX, NY)—After analyzing the blood of a survivor of the 2013-16 Ebola outbreak, a team of scientists from academia, industry and the government has discovered the first natural human antibodies that can neutralize and protect animals
Researchers develop Marburg virus treatment effective five days after infection
5
Apr
Contact: Donna Ramirez donna.ramirez@utmb.edu 409-772-8791 FOR IMMEDIATE RELEASE April 5, 2017 Virus causes hemorrhagic fever often leading to death April 5, 2017 – GALVESTON, Texas – An antibody treatment successfully protected nonhuman primates against the deadly Marburg and Ravn viruses even when given five days after becoming infected, according to
LeafBio Announces NEJM Publication of ZMapp™ Clinical Trial
13
Oct
Contact: Kerry Lion klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE October 12, 2016 Therapy to Treat Ebola Shows Promise October 12, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today that results from the PREVAIL II clinical trial of ZMapp™ for treatment of Ebola
Mapp Bio Receives HHS Funding for Expanded Access Protocol for Ebola Treatment
8
Aug
Contact: Perry Sacks psacks@skdknick.com 202-464-6611 FOR IMMEDIATE RELEASE August 8, 2016 Funds Will Allow Ebola Patients Expanded Access to Experimental Treatment August 8, 2016 – SAN DIEGO – Today, Mapp Biopharmaceutical, Inc. (Mapp Bio) announced it has received funding from Biomedical Advanced Research and Development Authority (BARDA), part of
LeafBio Announces Conclusion of ZMapp™ Clinical Trial
23
Feb
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE February 23, 2016 LeafBio Announces Conclusion of ZMapp™ Clinical Trial Therapy to Treat Ebola Shows Promise February 23, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today results from the Prevail II clinical trial
Clinical Trials Begin on Antibody-based Prevention of HIV and Genital Herpes
7
Jan
Contact: Kerri Lyon klyon@skdknick.com 917-348-2191 FOR IMMEDIATE RELEASE January 07, 2016 Clinical Trials Begin on Antibody-based Prevention of HIV and Genital Herpes Leaf Bio’s MB66 Developed as Multipurpose Prevention Technology January 7, 2016 – SAN DIEGO – LeafBio, Inc., the commercial arm of Mapp Biopharmaceutical, Inc., announced today that